RESUMEN
Objective:To investigate the therapeutic effect of Wenxin granule combined with sotalol on patients with arrhythmia and its influence on the levels of plasma angiotensin Ⅱ(Ang Ⅱ), C-reactive protein (CRP) and NT-proBNP.Methods:From January 2018 to October 2019, 162 patients with arrhythmia admitted to Taizhou Central Hospital were divided into observation group (81 cases) and control group (81 cases) according to the random digital table method.The control group was treated with sotalol, and the observation group was treated with Wenxin granule on the basis of the control group.The course of treatment in both two groups was 2 months.The changes of cardiac function, Ang Ⅱ, CRP and NT-proBNP levels, as well as adverse reactions were compared before and after treatment.Results:The total effective rate of the observation group (92.59%, 75/81) was higher than that of the control group (77.78%, 63/81) (χ 2=7.044, P<0.05). After treatment, the LVEDD [(53.18±3.09)mm] and LVESD [(52.19±2.35)mm] in the observation group were lower than those in the control group [(58.97±2.73)mm and (57.79±2.65)mm], while the SV [(76.93±3.67)mL] and LVEF [(53.90±2.64)%] in the observation group were higher than those in the control group [(71.35±2.87)mL and (46.75±2.18)%], the differences were statistically significant ( t=12.638, 14.230, 10.779, 18.795, all P<0.05). The plasma AngⅡ [(96.52±12.16)ng/L], CRP [(4.30±0.69)mg/L] and NT-proBNP [(394.25±47.15)ng/L] in the observation group were lower than those in the control group [(135.42±23.15)ng/L, (6.27±0.78)mg/L and (565.29±56.72)ng/L] ( t=13.389, 17.025, 20.870, all P<0.05). The incidence of adverse reactions in the observation group (11.11%) was lower than that in the control group (30.86%) (χ 2=9.529, P<0.05). Conclusion:Wenxin granule combined with sotalol is effective in the treatment of arrhythmia, which can reduce the plasma levels of Ang Ⅱ, CRP and NT-proBNP, improve the heart function and has no obvious adverse reactions.